Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
News|Webcasts|October 8, 2025
AI Everywhere: Architecting the Future of Clinical Trials
Author(s)Medidata
Listen
0:00 / 0:00
Webinar Date/Time: Wed, Oct 22, 2025 11:30 AM EDT
Ready to Lead the Way in AI-Driven Clinical Development? The clinical trial landscape is evolving at an incredible speed. The challenges are real; rising costs, data overload, and complex protocols can slow your progress. But what if you could face these challenges and turn them into a competitive advantage?
Register Free:
Clinical trials are more complex than ever — and while the promise of AI is immense, many organizations struggle to move beyond pilots. This webinar will show you how to turn AI aspiration into real-world impact with the power of agentic AI.
Join our panel-style discussion with experts from AbbVie, Everest, and Medidata on the state of AI in clinical trials. You’ll gain a clear view of what’s holding adoption back — from fragmented data to platform gaps — and see how Medidata’s end-to-end, AI-powered platform is designed to overcome these challenges.
Through real examples, you’ll discover how forecasting and simulation at the trial design stage can accelerate enrollment, boost efficiency, and improve trial outcomes — ultimately getting life-saving therapies to patients faster.
This session is designed for clinical operations leaders, R&D decision-makers, and anyone driving AI adoption in clinical trials.
What You’ll Learn
- A Smarter Platform: How a purpose-built, clinically fluent AI platform streamlines workflows and delivers insights at every stage.
- Predictive Power: How the industry’s most comprehensive dataset drives actionable forecasts and de-risks trials.
- Faster Results: How AI agents can automate routine tasks, free up teams for high-value work, and speed the delivery of breakthrough therapies.
Speakers:
Lisa Moneymaker
Chief Strategy Officer
Medidata
Brooks Fowler
VP of Clinical Data Strategy and Operations
AbbVie
Joshua Hartman
SVP Platform AI
Medidata
Manu Aggarwal
Partner
Everest Group
Register Free:
Related to this article
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
Participant engagement depends more on clarity and understanding than on gamification or incentives, requiring engagement embedded into trial workflows as a core design component rather than a peripheral consideration
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, outlines what it takes to move beyond transactional engagement and treat patient advocacy organizations as long-term partners in the science and the care.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Clinical trials have spent decades perfecting data capture, but the execution layer underneath it, including decision workflows, data collection design, and lab connectivity, remains fragmented in ways that limit what AI can realistically deliver and that quietly compromise the scientific validity of the data itself.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, describes how shifting patient engagement from protocol review to endpoint selection transforms both the quality of trial data and the experience of participation.